• 6/2/2005
  • Vienna, Austria
  • press release
  • PR Newswire (www.prnewswire.com)

CEL-SCI Corporation has been issued a new U.S. patent covering its cancer drug, Multikine(R). The patent, U.S. Patent No. 6,896,879, is titled, “A Method Of Pre-Sensitizing Cancer Prior To Treatment With Radiation And/Or Chemotherapy And A Novel Cytokine Mixture.”

This invention relates to a breakthrough method for pre-sensitizing cancer with Multikine prior to a therapeutic treatment such as chemotherapy, radiation therapy or immunotherapy. CEL-SCI’s drug Multikine is effective in inducing cancerous cells’ entry into the cell cycle phase thereby increasing their vulnerability to chemotherapy, radiation therapy and immunotherapy.

Maximilian de Clara, President of CEL-SCI, said, “This patent should protect one of the largest applications for Multikine, namely its use to increase the success of radiation and chemotherapy, for a long time. Our planned Phase III clinical trial of head and neck cancer patients will administer Multikine therapy as a part of first-line treatment prior to surgery followed by post surgery radiation or concurrent chemoradiotherapy.”

Multikine is an immunotherapeutic agent consisting of a mixture of
naturally occurring cytokines, including interleukins, interferons, chemokines and colony-stimulating factors, currently being developed for treatment of cancer.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.